Clinical Trial Update: Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of RMC-4630 and sotorasib in KRAS G12C-mutant non-small cell lung cancer after prior therapies has completed and post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LUMAKRAS (sotorasib)
• RMC-4630

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-01-06